KEYNOTE SPEAKERS

Inflection Points in Cancer Diagnostics
Stanley N. Lapidus, Chairman & Chief Executive Officer, Helicos BioSciences Corp. 

Franklyn G. Prendergast, M.D.,Ph.D., Director, Mayo Clinic Center for Individualized Medicine

HIGHLIGHTED PRESENTATIONS

The State of No-Union in the Cancer Diagnostics Space: How to Maximize Strengths to Catalyze the Implementation of Clinically Useful Cancer Diagnostic Products
Jorge A. León, Ph.D., President, Leomics Consulting

Molecular and Systems Pathology in the Diagnosis and Prognosis of Cancer
Carlos Cordon-Cardo, M.D., Ph.D., Professor and Vice-Chair, Department of Pathology Professor and Member, Department of Urology Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University

Early Assessment of Key Challenges in Commercialization of New Biomarkers - Pre-Analytical, Analytical, and Clinical Performance Considerations
Gerard J. Davis, Ph.D., Research Scientist and Project Manager, Abbott Laboratories, Cancer Diagnostics R&D

Blood Based and Other Screening Tests for Cancer: Prospects and Realities
Peter Lance, M.D., Professor of Medicine, Molecular & Cellular, Biology, and Public Health Director, Health Research Alliance  Arizona, Tucson Program, Co-Director, Cancer Prevention and Control, Arizona Cancer Center

Held directly following the
Seventh Annual
Systems Integration in Biodefense
August 18-19, 2008
www.healthtech.com/btr/overview.aspx

and
Second Annual
Enabling Point-of-Care Diagnostics
August 19-20, 2008
www.healthtech.com/poc/overview.aspx